Keywords
Last Name
Institution

Jose Romero

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentPediatrics, College of Medicine
DivisionPeds Infectious Diseases
Address ACH Sturgis Building
800 Marshall Street
Mail Slot # 512-11
Little Rock AR 72202
Phone501-364-1416
vCardDownload vCard

    Collapse Research Funds 
    Collapse principal investigator
    Funding Agency: Cepheid - Title: Protocol 031S: Nasal Swab and Nasopharyngeal Swab Specimen Collection for use with Cepheid Flu and/or Flu/RSV - Start Date: 2017-08-01

    Funding Agency: Cepheid - Title: Nasal Swab and Nasopharyngeal Swab Specimen Collection for use with Cepheid Flu and/or Flu/RSV - Start Date: 2017-02-01

    Funding Agency: Cepheid - Title: Clinical Evaluation of the Xpert Xpress Strep A Assay on the GeneXpert Xpress System in a CLIA-Waived Environment Protocol 226 - Start Date: 2017-02-01

    Pass Through Agency: University of California San Francisco - Funding Agency: Patient Centered Outcomes Research Institute - Title: Kawasaki Disease Comparative Effectiveness Trial (KIDCARE) - Start Date: 2017-02-01

    Funding Agency: Meridian Bioscience, Inc - Title: Cytomegalovirus Research Stage- Pre-Clinical Study Protocol - Specimen Collection - Start Date: 2016-10-26

    Funding Agency: Cepheid - Title: Clinical Evaluation of the Xpress Flu/RSV CW Assay and Xpress Flu A/B CW Assay on the GeneXpert Xpress System in a CLIA-Waived Environment - Start Date: 2016-10-13

    Funding Agency: The Medicines Company - Title: An Open-Label, Dose-Finding Pharmacokinetics, Safety and Tolerability Study of a Single Dose Infusion of Meropenem-Vaborbactam in Pediatric Subjects from Birth to less than 18 YO with Serious Bacterial Infections - Start Date: 2016-07-01

    Funding Agency: Meridian Bioscience, Inc - Title: illumigen Kingella Sample Acquisition - Start Date: 2016-07-01

    Funding Agency: - Title: A Randomized, Double-Blind, Placebo-controlled, 2-Part Study of Orally Administered ALS-008176 to Evaluate the Safety, Tolerability, PK and PD of Single Ascending Dosing and Multiple Ascending Dosing in Infants Hosiptalized with RSV Infection - Start Date: 2015-12-21

    Pass Through Agency: Icon - Funding Agency: Regeneron Pharmaceuticals, Inc. - Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Huma Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants - Start Date: 2015-12-01

    Pass Through Agency: Social & Scientific Systems Inc. - Funding Agency: National Institute of Allergy and Infectious Diseases - Title: A Randomized Double-Blind, Phase 3 study comparing the efficacy and safety of high-titer versus low-titer anti-influenza immune plasma for the treatment of severe influenza A - Start Date: 2015-10-16

    Funding Agency: Alere Scarborough, Inc. - Title: Clinical Evaluation of an Improved BinaxNOW Influenza A&B Card - Start Date: 2015-09-30

    Pass Through Agency: Duke University - Office of Research Support - Funding Agency: National Institutes of Health - Title: Fungal Biomarkers for Diagnosis and Response to Therapy for Pediatric Candidemia - Start Date: 2015-06-09

    Funding Agency: Alere Scarborough, Inc. - Title: Clinical Evaluation of an Improved BinaxNOW Influenza A&B Card - Start Date: 2014-12-15

    Funding Agency: The Medicines Company - Title: An Open label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin Single Dose Infusion in Pediatric Subjects Less than 18 Years of Age with Suspected or Confirmed Bacterial Infections - Start Date: 2014-05-01

    Pass Through Agency: PPD Development, LP - Funding Agency: Biota SCientific Management Pty Ltd. - Title: Randomized, Parallel Dose, Phase 1/2 Safety and Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps Dry Powder Inhaler in Children with Naturally Acquired Influenza A or B - Start Date: 2014-01-01

    Pass Through Agency: Duke University - Office of Research Support - Funding Agency: National Institutes of Health - Title: Multi-Center Studies to Improve Diagnosis and Treatment of Pediatric Candidiasis - Start Date: 2014-01-01

    Funding Agency: Cerexa, Inc. - Title: A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, PK and Efficacy of Ceftaroline versus Ceftriaxone in Pediatric Subjects with Community-acquired Bacterial Pneumonia Requiring Hospitalization - Start Date: 2013-11-01

    Funding Agency: AstraZeneca - Title: A Phase I Study to Assess the Pharmacokinetis, Safety and Tolerability of a Single Dose of CAZ-AVI in Children from 3 months of age to < 18 Years Who are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection - Start Date: 2013-06-04

    Pass Through Agency: University of Alabama at Birmingham - Funding Agency: National Institutes of Health - Title: An Adaptive, Sequential Study Evaluating Prevention of Neonatal HSV Disease: Detection of Mternal HSV Shedding at Delivery, Followed by Preemptive Antiviral Therapy in Exposed Neonates - Start Date: 2013-01-01

    Funding Agency: Gilead Sciences, Inc. - Title: A Multi-Center, Outpatient, Surveillance Study of Respiratory Syncytial Virus (RSV) Infection and RSV-related Hospitalizations Among Subjects < 24 Months of Age with Medically Attended Respiratory Tract Infection - Start Date: 2012-11-20

    Funding Agency: BD Diagnostics - Title: BD Veritor System Clinical Evaluation for Rapid Detection of Respiratory Syncytial Virus- Reference Testing - Start Date: 2012-10-23

    Funding Agency: BD Diagnostics - Title: BD Veritor System Clinical Evaluation for Rapid Detection of RSV - Start Date: 2012-02-28

    Pass Through Agency: University of Alabama at Birmingham - Funding Agency: National Institutes of Health - Title: A PK, PD, and Resistance Evaluation of IV Ganciclovir in Premature Infants - Start Date: 2012-02-01

    Pass Through Agency: University of Alabama at Birmingham - Funding Agency: National Institutes of Health - Title: An Adaptive PK, PD, Concentration Response Investigation of CMX001 in the infants with Neonatal HSV, Followed by a Radnomized Assessment of Oral Valcyclovir vs. Oral Acyclovir Suppression - Start Date: 2012-02-01

    Funding Agency: National Institutes of Health - Title: A Pharmacokinetic, Pharmacodynamic, and Resistance Evaluation of IV Ganciclovir in Premature Infants - Start Date: 2012-02-01

    Funding Agency: National Institutes of Health - Title: An Adaptive, Sequential Study Evaluating Prevention of Neonatal HSV Disease: Detection of Maternal HSV Shedding - Start Date: 2012-02-01

    Pass Through Agency: University of Alabama at Birmingham - Funding Agency: National Institutes of Health - Title: A safety and Dose-Determining Study of CMX-001 in Infants with Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease) - Start Date: 2012-02-01


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Dufouil C, Beiser A, McLure LA, Wolf PA, Tzourio C, Howard VJ, Westwood AJ, Himali JJ, Sullivan L, Aparicio HJ, Kelly-Hayes M, Ritchie K, Kase CS, Pikula A, Romero JR, D'Agostino RB, Samieri C, Vasan RS, Chêne G, Howard G, Seshadri S. Revised Framingham Stroke Risk Profile to Reflect Temporal Trends. Circulation. 2017 Mar 21; 135(12):1145-1159. PMID: 28159800.
      View in: PubMed
    2. Olarte L, Lin PL, Barson WJ, Romero JR, Tan TQ, Givner LB, Hoffman JA, Bradley JS, Hultén KG, Mason EO, Kaplan SL. Invasive pneumococcal infections in children following transplantation in the pneumococcal conjugate vaccine era. Transpl Infect Dis. 2017 Feb; 19(1). PMID: 27862712.
      View in: PubMed
    3. Shoamanesh A, Preis SR, Beiser AS, Kase CS, Wolf PA, Vasan RS, Benjamin EJ, Seshadri S, Romero JR. Circulating biomarkers and incident ischemic stroke in the Framingham Offspring Study. Neurology. 2016 Sep 20; 87(12):1206-11. PMID: 27558379.
      View in: PubMed
    4. Shoamanesh A, Preis SR, Beiser AS, Vasan RS, Benjamin EJ, Kase CS, Wolf PA, DeCarli C, Romero JR, Seshadri S. Inflammatory biomarkers, cerebral microbleeds, and small vessel disease: Framingham Heart Study. Neurology. 2015 Feb 24; 84(8):825-32. PMID: 25632086; PMCID: PMC4345647.
    5. Arthur C, Tang X, Romero JR, Gossett JG, Harik N, Prodhan P. Stenotrophomonas maltophilia infection among young children in a cardiac intensive care unit: a single institution experience. Pediatr Cardiol. 2015 Mar; 36(3):509-15. PMID: 25293429.
      View in: PubMed
    6. Shoamanesh A, Masoud H, Furey K, Duerfeldt K, Lau H, Romero JR, Pikula A, Teal P, Nguyen TN, Kase CS, Babikian VL. Larger A1/M1 diameter ratio predicts embolic anterior cerebral artery territorial stroke. Stroke. 2014 Sep; 45(9):2798-800. PMID: 25082805.
      View in: PubMed
    7. Coutinho P, Vega C, Pojoga LH, Rivera A, Prado GN, Yao TM, Adler G, Torres-Grajales M, Maldonado ER, Ramos-Rivera A, Williams JS, Williams G, Romero JR. Aldosterone's rapid, nongenomic effects are mediated by striatin: a modulator of aldosterone's effect on estrogen action. Endocrinology. 2014 Jun; 155(6):2233-43. PMID: 24654783; PMCID: PMC4020933.
    8. Demissie DE, Kaplan SL, Romero JR, Leake JA, Barson WJ, Halasa NB, Byington CL, Shetty AK, Tan TQ, Hoffman JA, Lin PL, Edwards KM, Mason EO, Cooperstock MS. Altered neutrophil counts at diagnosis of invasive meningococcal infection in children. Pediatr Infect Dis J. 2013 Oct; 32(10):1070-2. PMID: 23736141.
      View in: PubMed
    9. Romero JR, Modlin J. Principles and Practice of Infectious Diseases. Coxsackieviruses. 2013.
    10. Romero JR. Feigin & Cherry's Textbook of Pediatric Infectious Diseases. West Nile Virus. 2013.
    11. Hulten KG, Kaplan SL, Lamberth LB, Barson WJ, Romero JR, Lin PL, Bradley JS, Givner LB, Tan TQ, Hoffman JA, Mason EO. Changes in Streptococcus pneumoniae serotype 19A invasive infections in children from 1993 to 2011. J Clin Microbiol. 2013; 51:1294-1297.
    12. Romero JR, Modlin J. Principles and Practice of Infectious Diseases. Introduction to the Human Enteroviruses and Parechoviruses. 2013.
    13. Martin K, Romero JR. Comprehensive Pediatric Hospital Medicine. Central Nervous System Infections. 2013.
    14. Romero JR, Jacobs RF. Textbook of Pediatric Infectious Diseases. Fungal Meningitis. 2013.
    15. Romero JR, Modlin J. Principles and Practice of Infectious Diseases. Polioviruses. 2013.
    16. Stellrecht KA, Lamson DA, Romero JR. Manual of Clinical Microbiology. Entroviruses and parechoviruses. 2013.
    17. Kaplan SL, Barson WJ, Lin PL, Romero JR, Bradley JS, Tan TQ, Hoffman JA, Givner LB, Mason EO Jr. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2013; 32:203-207.
    18. Romero JR. Infections of the Central Nervous System. Viral Meningitis and Aseptic Meningitis. 2013.
    19. Romero JR, Modlin J. Principles and Practice of Infection Diseases. Parechoviruses. 2013.
    20. Martin K, Romero JR. Feigin & Cherry's Textbook of Pediatric Infectious Diseases. St. Louis Encephalitis. 2013.
    21. Wheeler JG, Romero JR. Tick-related illnesses in Arkansas: myths and management. J Ark Med Soc. 2012 May; 108(12):272-3. PMID: 22679681.
      View in: PubMed
    22. Romero J. Enteroviruses in Humans. 2012.
    23. Kaplan SL, Barson, W, Lin, P, Romero JR, Bradley, J, Tan, T, Hoffman, J. Early Trends for Invasive Pneumococcal Infections in Children Following the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine. 49th Annual Meeting of the Infectious Diseases Society of America. 2012.
    24. Demissie DE, Kaplan SL, Romero JR, Leake JAD, Barson WJ, Halasa NB, Byington CL, Shetty AK, Tan TQ, Hoffman JA, Lin PL, Edwards KM, Mason EO, Cooperstock MS. Neutrophil Profile at Diagnosis of Invasive Meningococcal Infection in Chil. Pediatric Academic Societies' Meeting. 2012.
    25. Linam WM, Gilliam CH, Honeycutt MD, Wisdom CM, Swearingen CJ, Romero JR. Parental Perceptions about Mandatory Influenza Immunization of Pediatric Healthcare Workers. Pediatric Academic Societies' Meeting. 2012.
    26. McKee SG, Linam WM, Romero JR. Methicillin-resistant Staphylococcus aureus epidural abscesses in children. J Investigative Med. 2012; 40.
    27. Martin KC, Romero JR. Curbside Consultation in Pediatric Infectious Diseases : 49 clinical questions. What Is the Best Empiric and/or Prophylactic Therapy for a Child in Whom You Suspect a Tick-borne Infection?. 2012.
    28. Martin KC, Romero JR. Curbside Consultation in Pediatric Infectious Diseases : 49 clinical questions. What Are the Best Prophylactic Measures to Tell Families to Use to Prevent Tick Bites? At What Age Are Agents Such as DEET and Picaridin Safe to Use?. 2012.
    29. Martin KC, Romero JR. Curbside Consultation in Pediatric Infectious Diseases : 49 clinical questions. In What Part of the United States is Lyme Disease Seen, How is Diagnosis Confirmed, and What is the Appropriate Treatment?. 2012.
    30. Bell J, Anderson EJ, Greene WH, Romero JR, Merchant M, Selvarangan R. A Multicentered evaluation of the performance characteristics of the BD Veritor System for rapid RSV detection. 50th Annual Meeting of the Infectious Diseases Society of America. 2012.
    31. Romero JR. Principles and Practice of Pediatric Infectious Diseases. 292-297. 2012; 43.
    32. Martin KC, Romero JR. Curbside Consultation in Pediatric Infectious Disease: 49 clinical questions. When Are Tick-borne Infections Typically Seen in the United States, and When Does the Peak Time Occur?. 2012.
    33. Fornage M, Debette S, Bis JC, Schmidt H, Ikram MA, Dufouil C, Sigurdsson S, Lumley T, DeStefano AL, Fazekas F, Vrooman HA, Shibata DK, Maillard P, Zijdenbos A, Smith AV, Gudnason H, de Boer R, Cushman M, Mazoyer B, Heiss G, Vernooij MW, Enzinger C, Glazer NL, Beiser A, Knopman DS, Cavalieri M, Niessen WJ, Harris TB, Petrovic K, Lopez OL, Au R, Lambert JC, Hofman A, Gottesman RF, Garcia M, Heckbert SR, Atwood LD, Catellier DJ, Uitterlinden AG, Yang Q, Smith NL, Aspelund T, Romero JR, Rice K, Taylor KD, Nalls MA, Rotter JI, Sharrett R, van Duijn CM, Amouyel P, Wolf PA, Gudnason V, van der Lugt A, Boerwinkle E, Psaty BM, Seshadri S, Tzourio C, Breteler MM, Mosley TH, Schmidt R, Longstreth WT, DeCarli C, Launer LJ. Genome-wide association studies of cerebral white matter lesion burden: the CHARGE consortium. Ann Neurol. 2011 Jun; 69(6):928-39. PMID: 21681796; PMCID: PMC3122147.
    34. Romero JR, Selvarangan R. The human Parechoviruses: an overview. Adv Pediatr. 2011; 58(1):65-85. PMID: 21736976.
      View in: PubMed
    35. Romero JR. Cecil Medicine. Enteroviruses (Poliovirus, Coxsakieviruses, Echoviruses, and Others). 2011.
    36. Romero J. Rudolph's Pediatrics. Enteroviruses. 2011.
    37. Sanders RC, Diokno RM, Romero JR. MRSA Infections in Children. J AR Med Soc. 2011; 107:287-290.
    38. Nolte FS, Tang YW, Robinson CC, Rogers B, Kehl KS, Rand KH, Oberste MS, Rotbart HA, Romero JR, Nyquist AC, Persing DH. Evaluation of a Rapid and Completely Automated Real-time Reverse Transcriptase Polymerase Chain Reaction Assay for the Diagnosis of Enteroviral Meningits. J Clin Micro. 2011; 49:528-533.
    39. Romero JR, Rothbart HA, Nyquist AC, Nolte F. Enteroviral Meningitis Does Not Exclude Concurrent Bacterial Meningitis, Authors’ Reply. J Clin Micro. 2011; 49:3440-3441.
    40. Stellrecht KA, Lamson DA, Romero JR. Entroviruses and parechoviruses. Manual of Clinical Microbiology. 2011; 1388-99.
    41. Romero JR. Rudolph's Pediatrics. Enterovirus Infections. 2011; 306.
    42. Nolte FS, Rogers BB, Tang YW, Oberste MS, Robinson CC, Kehl KS, Rand KA, Rotbart HA, Romero JR, Nyquist AC, Persing DH. Evaluation of a rapid and completely automated real-time reverse transcriptase PCR assay for diagnosis of enteroviral meningitis. J Clin Microbiol. 2011 Feb; 49(2):528-33. PMID: 21159942; PMCID: PMC3043510.
    43. Romero JR, Stewart DL, Buysman EK, Fernandes AW, Jafri HS, Mahadevia PJ. Serious early childhood wheezing after respiratory syncytial virus lower respiratory tract illness in preterm infants. Clin Ther. 2010 Dec; 32(14):2422-32. PMID: 21353110.
      View in: PubMed
    44. Romero JR, Et al. Serious early childhood wheezing following respiratory syncytial virus lower respiratory tract infections in preterm infants. 2010.
    45. Romero J. Antimicrobial Therapy and Vaccines, Volume II. Enteroviruses (Coxsackieviruses, Echoviruses and Numbered Enteroviruses) and Parechoviruses. 2010.
    46. Carbonell-Estrany X, Simoes EAF, Dagan R, Hall CB, Harris B, Hultquist M, Connor EM, Losonsky GA, Romero JR. Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: A Noninferiority Trial. Pediatrics. 2010; 125:e35-e51.
    47. Juretschko SM, Romero JR, Harik N. Failur of Automated Identification Systems to Detect Methicillin Resistance of Staphylococcus aureus in Patients with Cystic Fibrosis. Infectious Diseases Society of America. 2010.
    48. Kimberlin DW, Shalabi M, Abzug MJ, Lang D, Jacobs RF, Storch G, Bradley JS, Wade K, Ramilo O, Romero JR, Shelton M, Leach C, Guzamn-Cottrill J, Robinson J, Abughali N, Englund J, Griffin J, Jester P, Cloud GA, Whitley RJ. Safety of oseltamivir vs. adamantanes in children under 12 months of age: A retrospective chart review. Pediatr Infect Dis J. 2010; 29:195-198.
    49. Romero JR, Linam WM, Honeycutt M, Wisdom C. Clinical Characteristics of Infants <6 Months of Age Hospitalized with 2009 H1N1 Influenza Virus Infection. Pediatric Research. 2010.
    50. Romero JR, Stewart DL, Busyman EK, Fernandes AW, Jafri HS, Mahadevia PJ. Serious Early Childhood Wheezing Following Respiratory Syncytial Virus Lower Respiratory Tract Illness in Preterm Infants. Clin Ther. 2010; 32:2422-2432.
    51. Romero JR, O'Connor J. Pediatric Practice: Gastroenterology. Viral Hepatitis. 2010; 24.
    52. Graham J, Shirm SW, Storm E, Linam WM, Romero JR. Impact of 2009 H1N1 Influenza on a Pediatric Emergency Department. Pediatric Research. 2010.
    53. Romero JR, O'Connor J. Pediatric Practice: Gastroenterology, Hepatology, and Nutrition. Viral Hepatitis. 2010.
    54. Stewart D, Romero JR, Busyman E, Fernandes AW, Mahadevia PJ. Healthcare costs of preterm infants due to medically attended respiratory syncytial virus lower respiratory infection in the first year of life. Curr Med Res Opin. 2009; 25:2795-80.
    55. Romero J. Textbook of Pediatric Infectious Diseases. West Nile virus infections. 2009; 188.
    56. Jurectschko S, Beavers-May TK, Hemphill C, Romero JR, Stovall SH. Superior Detection of Kingella kingae and Staphylococcus aureus in pediatric osteoarticular infections using molecular assays. 2009.
    57. Romero JR. Clinical Virology. Enteroviruses. 2009; pp 1031-1062.
    58. Juretschko,SM, Romero JR, Harik,N. Failure of Automated Identification Systems to Detect Methicillin Resistance of Staphylococcus aureus in Patients with Cystic Fibrosis. 47th Annual Infectious Diseases Society of America Meeting. 2009.
    59. Stewart D, Romero J, Buysman EK, Fernandes AW, Mahadevia PJ. Total health care cost of preterm infants with medically attended respiratory syncytial virus lower respiratory tract infection. Infectious Diseases Society of America. 2008; 495 Abstract K - 1429.
    60. Witt D, Marcon M, Romero J, Sawyer M, Storch G, Dunn J, Schnurr D, Kok W. Multi-Center Evaluation of a Real Time NASBA Best for Detection of Enterovirus in Cerebrospinal Fluid From Pediatric Patients. 24th Annual Clinical Virology Symposium. 2008.
    61. Romero J, Varman M, Barton L. Neurologic Manifestations of Pediatric Infectious and Immunologic Diseases. Togaviruses. 2008.
    62. Romero J. Neurologic Manifestations of Pediatric Infectious and Immunologic Diseases. Arboviruses. 2008.
    63. Romero J, Simonsen KA. Powassan Encephalitis and Colorado Tick Fever. Infectious Diseases Clinics of North America. 2008; 22:545-559.
    64. Varman MV, Romero J, Cusick RA, Esposito PW, Armstrong D. Polymicrobial wound infection and nerve injury secondary to a non-human primate bite. Infect Med. 2008; 25:120-127.
    65. Romero J. Neurologic Manifestations of Pediatric Infectious and Immunologic Diseases. Orthopoxviruses. 2008.
    66. Newland JG, Romero J. Neurologic Manifestations of Pediatric Infectious and Immunologic Diseases. Myxoviruses. 2008.
    67. Romero J. Group B Coxsackievirus Infections in Children. Curr Top Microbiol Immunol. 2008; 323:223-240.
    68. Newland JG, Romero J. The Encyclopedia of Public Health. Enteroviruses. 2008.
    69. Truemper EJ, Romero J. West Nile virus. Pediatr Annals. 2007; 36:414-22.
    70. Jafri HS MD, Ramilo O, Makari D, Charsha-May D, Romero J. Diagnostic virology practices for respiratory syncytial virus (RSV) and influenza virus among children in the hospital setting: a nationa survey. Pediatr Infect Dis J. 2007; 26:956-58.
    71. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, Kemble G, Connor EM, Romero J. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007; 356:685-696.
    72. Mix AC, Romero J. Comprehensive Pediatric Hospital Medicine. Central Nervous System Infections. 2007.
    73. Newland JG, Romero J. Diagnosis fo viral encephalidites: Zoonotic-associated viruses. Concise Reviews in Pediatric Infectious Diseases, Pediatr Infect Dis J. 2006; 25(8):739-41.
    74. Herrera V, Babcock B, Bastola DR, Romero J, Gebhart C. Performance evaluation of an in-house enterovirus assay over a two year period. 22nd Annual Clinical Virology Symposium. 2006.
    75. Romero J. Manual of Clinical Microbiology. Entroviruses and parechoviruses. 2006.
    76. Ramilo O, Romero J, Jafri H, Makari D, Charsha-May D. Diagnostic testing for respiratory syncytial virus and influenza in the hospital setting: A national survey. American Academy of Pediatrics National Conference and Exhibition. 2005.
    77. Bastola DR, Romero J. Molecular epidemiology of Coxsackievirus B3 (CBV3) in the United States: 1949-1998. 24th Annual Meeting of the American Society for Virology. 2005; W27-8.
    78. Varman M, Romero J, Cornish NE, Manley J, Meza JL, Zach TL, Chartrand SA. Characterization and mechanisms of resistance of group B streptococcal isolates obtained at a community hospital. Euro J Clin Microbiol Infect Dis. 2005; 24:431-433.
    79. Romero J, Stacy RD. Minority Behavioral Risk Factor Survey in Douglas County: A Special Report to Nebraska Office of Minority Health. A Collaborative report with Douglas, Sarpy/Cass County, Nebraska Health Departments, Urban League of Nebraska, Chicano Awareness Center, University of Nebraska Medical Center, and University of Nebrask at Omaha. 2004; 1-34.
    80. Romero J, Cohen A, Boron M, Rankin M, Synagis Outcomes Registry Study Group. Respiratory Syncytial Virus (RSV) prophylaxis in minority populations; results from the Palivizumab Outcomes Registry 2002-2003. Pediatric Research. 2004; 237A.
    81. Newland JG, Romero J. Examination of the plasticity of the puff binding region of Coxsackievirus B3 (CVB3). American Academy of Pediatrics National Conference and Exhibition. 2004; Section on Residents.
    82. Romero J, Ramilo O, Jafri H, Makari D, Charsha-May D. Diagnostic virology practices for respiratory syncytial virus (RSV) and influenza virus among children in the hospital setting: a national survey. Infectious Diseases Society of America. 2004; 129.
    83. Romero J. Respiratory Syncytial Virus (RSV) prophylaxis in minority populations; results from the Palivizumab Outcomes Registry 2002-2003. 2004.
    84. Romero J. Experience with limited Phase I smallpox vaccination in a Midwestern children's hospital. 2004.
    85. Romero J, Allensworth CD, Pour AM. Experience with limited Phase I smallpox vaccination in a Midwestern children's hospital. Pediatric Research. 2004; 4.
    86. Romero J. Diagnostic virology practices for respiratory syncytial virus (RSV) and influenza virus among children in the hospital setting: a nationa survey. 2004.
    87. Romero J. Impact of PCR detection of evteroviral (EV) infection of the management of febrile neonates. 2003.
    88. Romero JR. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Pediatr Infect Dis J. 2003 Feb; 22(2 Suppl):S46-54. PMID: 12671452.
      View in: PubMed
    89. Romero J, Rotbart HA. Manual of Clinical Microbiology. Enteroviruses. 2003.
    90. Romero J, Newland JG. Viral Meningitis and Encephalitis: Traditional and emerging viral agents. Semin Pediatr Infect Dis. 2003; 14:72-82.
    91. Newland JG, Romero J, Sarica A, Lych JC. Impact of PCR detection of evteroviral (EV) infection of the management of febrile neonates. Pediatric Research. 2003; 4.
    92. Newland JG, Romero J, Varman M, Drake C, Holst A, Safranek T, Subbarao K. Encephalitis associated with influenza B infection in two children and a review of the literature. Clin Infect Dis. 2003; 36:e87-95.
    93. Dunn JJ, Bradrick SS, Chapman NM, Tracy SM, Romero J. The stem loop II within the 5' nontranslated region of clinical Coxsackievirus B3 genomes determines cardiovirulence phenotype in murine model. J Infect Dis. 2003; 187:1552-1561.
    94. Romero J. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998-2002: Results from four years of palivizumab usage. Pediatr Infect Dis J. 2003; 22(2):Supp: 46-54.
    95. Romero J, Allensworth C, Pour AM. Evaluation of phase I vaccination in Douglas County, Nebraska. Infectious Diseases Society of America. 2003; 173.
    96. Varman M, Romero J, Cornish NE, Yam PA. Time to detection of respiratory viruses using meixed cell shell vial cultures: 2 vs. 5 days. 41st Annual Infectious Diseases Society of America Meeting, Program and Abstracts. 2003; 92.
    97. Romero J, Kimberlin DW. Molecular diagnosis of viral infections of the central nervous system. Clin Lab Med. 2003; 23:843-865.
    98. Abzug MJ, Cloud G, Bradley J, Sánchez P, Romero J, Powell D, Lepow M, Mani C, Capparelli EV, Blount S, Lakeman F, Whitley RJ, Kimberly DW, Collaborative Antiviral Study Group. Double blind, placebo-controlled trial of pleconaril in infants with enterovirus meningitis. Pediatr Infect Dis J. 2003; 22(4):335-341.
    99. Romero J. Spectrum of neonatal enteroviral disease over an 8-year period. 2002.
    100. Romero J. Changing susceptibility of group B Streptococcus from a community hospital in a mid-sized Midwestern city. 2002.
    101. Romero J, Newland JG. Antimicrobial Therapy and Vaccines. Enteroviruses (Polioviruses, coxsackieviruses, echoviruses and numbered enteroviruses). 2002.
    102. Romero J. Diagnosis and management of enteroviral infections of the central nervous system. Curr Infect Dis Rep. 2002; 4:309-316.
    103. Varman M, Cornish NE, Zach TL, Romero J. Changing susceptibility of group B Streptococcus from a community hospital in a mid-sized Midwestern city. Pediatric Research. 2002.
    104. Newland JG, Romero J, Sarica A, Zach TL, Linder K. Spectrum of neonatal enteroviral disease over an 8-year period. Infectious Diseases Society of America. 2002; 50.
    105. Tracy S, Drescher KM, Chapman NM, Kim KS, Carson SD, Pirruccello S, Lane PH, Romero J, Leser JS. Toward testing the hypothesis that group B coxsackieviruses (CVB) trigger insulin-dependent diabetes: Inoculating NOD mice with CVB markedly lowers diabetes incidence. J Virol. 2002; 76(23):12097-12111.
    106. Romero J. Molecular epidemiology of coxsackievirus B3 in the United States: 1949-1998. 2001.
    107. Rotbart HA, Webster AD, Pleconaril Treatment Registry Group. Treatment of potentially life-threatening enterovirus with pleconaril. Clin Infect Dis. 2001; 32:228-235.
    108. Willis TMS, Hopp RJ, Romero J, Larsen PD. The protective effect of brachial plexus palsy in Purpura fulminans. Pediatr Neurol. 2001; 24(5):379-381.
    109. Boyd ZS, Bradrick SS, Cornish N, Carden BM, Romero J. Mutations within the IRES of echovirus 12 confer a novel pathogenic phenotype to and echovirus 12-coxsackeivirus B3 chimera. 30th Annual Meeting of the American Society for Virology. 2001.
    110. Bradrick SS, Romero J. Polioviruses. 2001; 1-7.
    111. Newland JG, Romero J, Subbarao K, Safranek T. Encephalitis associated with influenza B infections: A case series in children. Infectious Diseases Society of America. 2001; 66.
    112. Romero J. Mutations within the IRES of echovirus 12 confer a novel pathogenic phenotype to and echovirus 12-coxsackeivirus B3 chimera. 2001.
    113. Kimberlin DW, Lin CY, Jacobs RF, Et al.,. Natural history of neonatal herpes simplex virus infections. Pediatrics. 2001; 108(2004):223-229.
    114. Romero J. Encephalitis associated with influenza B infections: A case series in children. 2001.
    115. Parasuraman TV, Frenia K, Romero JR. Enteroviral meningitis: Cost of illness and considerations for the economic evaluation of potential therapies. Pharmacoeconomics. 2001; 19(1990):3-12.
    116. Romero J. Enteroviruses in humans. 2001; 1-7.
    117. Bradrick SS, Lieben EA, Carden BM, Romero J. A predicted secondary structural domain within the internal ribosome entry site of echovirus 12 mediates a cell type specific block to viral replication. J Virol. 2001; 75(14):6472-6481.
    118. Romero J. Pleconaril: A novel antipicornaviral drug. Exp Opin Investig Drugs. 2001; 10(2):369-379.
    119. Romero J. Further mapping of the coxsackievirus B3 (CVB3) 5' nontranslated region (5'NTR) cardiovirulence determinant. 2000.
    120. Romero J. Identification of the major determinant of cardiovirulence of coxsackievirus B3. 2000.
    121. Dunn JJ, Romero J, Wasserman R, Rotbart HA. Stable enterovirus genome over a seven-year period in a patient with agammaglobulinemia and chronic infection. J Infect Dis. 2000; 182:298-301.
    122. Parasuraman TV, Deverka PA, Toscini MR, Meningitis Consensus Panel. Estimating the economic impact of viral meningitis in the United States. Infect Med. 2000; 17:417-427.
    123. Bradrick SS, Carden BM, Dunn JJ, Romero J. Further mapping of the coxsackievirus B3 (CVB3) 5' nontranslated region (5'NTR) cardiovirulence determinant. 29th Annual Meeting of the American Society for Virology. 2000.
    124. Willian S, Tracy S, Chapman N, Leser S, Romero J, Shapiro B, Currey K. Mutations in a conserved enteroviral RNA oligonucleotide sequences affect positive strand viral RNA synthesis. Arch Virol. 2000; 145(10):2061-2086.
    125. Romero J, Tracy SM, Chapman NM, Dunn JJ. Identification of the major determinant of cardiovirulence of coxsackievirus B3. Pediatric Research. 2000.
    126. Dunn JJ, Chapman N, Tracy S, Romero J. Genomic determinants of cardiovirulence in coxackievirus B3 clinical isolates: Localizaion to the 5' nontranslated region. J Virol. 2000; 74:4787-4794.
    127. Romero J. Coxsackievirus B3 (CVB3) genotypes in the United States (US). 1999.
    128. Romero J. Molecular epidemiology of coxsackievirus B3 (CVB3) in the United States--1954-1979. 1999.
    129. Romero J. Cardiovirulence determinants among naturally occurring isolates of coxsackievirus B3 reside within the 5' nontranslated region. 1999.
    130. Romero J. Pleconaril treatment of vaccine-acquired poliovirus. 1999.
    131. Modlin J, Reiss M, Romero J, Et al. Development and validation of a decision analytic framework to evaluate the economic impact of suspected meningitis. Internationa Society for Pharmacoeconomics and Outcomes Research Meeting. 1999.
    132. Modlin J, Reiss M, Romero J. Estimating the economic impact of viral meningitis in the United States. Internationa Society for Pharmacoeconomics and Outcomes Research Meeting. 1999.
    133. Dunn JJ, Tracy SM, Chapman NM, Romero J. Deteminants of cardiovirulence in coxsackievirus B3 (CVB3) clinical isolates localize to the 5' nontranslated regions (5'NTR). 18th Annual Meeting of the American Society for Virology. 1999.
    134. Romero J, Gross T, Abromowitch M, Jung L. Pleconaril treatment of vaccine-acquired poliovirus. Pediatric Research. 1999.
    135. Romero J, Dunn JJ, Tracy SM, Et al. Cardiovirulence determinants among naturally occurring isolates of coxsackievirus B3 reside within the 5' nontranslated region. Pediatric Research. 1999.
    136. Sawyer MH, Saez-Llorenz X, Aviles CL, O'Ryan M, Romero J. Oral Pleconaril reduces the duration and severity of enteroviral meningitis in children. Pediatric Research. 1999.
    137. Modlin J, Reiss M, Romero J, Et al. Estimating the economic impact of viral meningitis in the United States. Internationa Society for Pharmacoeconomics and Outcomes Research Meeting. 1999.
    138. Bradrick SS, Lieben EA, Romero J. Nonreceptor determinants of growth restriction reside within the echovirus 12 5' nontranslated region. 18th Annual Meeting of the American Society for Virology. 1999.
    139. Romero J. Reverse transcription-polymerase chain reaction detection of the enteroviruses: Overview and clinical utility in pediatric enteroviral infections. Arch Pathol Lab Med. 1999; 123:1161-1169.
    140. Heuermann KG, Romero J, Abromowitch MA, Gordon BG, Gross TG. Fatal coagulase negative staphylococci infection after bone marrow transplantation in a patient with persistent adverse reactions to vancomycin. Am J Pediatr Hematol/Oncol. 1999; 21:80-81.
    141. Romero J, Bradrick SS, Schnurr D, Oberste S, Et al. Coxsackievirus B3 (CVB3) genotypes in the United States (US). Infectious Diseases Society of America. 1999; 164.
    142. Romero J, Schnurr D, Oberste MS, Bradrick SS, Et al. Molecular epidemiology of coxsackievirus B3 (CVB3) in the United States--1954-1979. 18th Annual Meeting of the American Society for Virology. 1999.
    143. Romero J. Enteroviruses: Diagnosis, screening, and surveillance. Infect Med. 1999; 16(Suppl D ):11-20.
    144. Romero J. Molecular and phenotypic characterization of a myocarditic coxsackievirus B3 (CVB3) isolate. 1998.
    145. Romero J. Reverse transcription-polymerase chain reaction diagnosis of enterovirus infections in febrile children results in reduced health care expenditures. 1998.
    146. Romero J. Reverse transcription-polymerase chain reaction diagnosis of enterovirus infections in febrile children reduces duration of hospitalization, antibiotic administration and results in reduced health care costs. 1998.
    147. Romero J. Impact of reverse transcription-polymerase chain reaction diagnosis of enterovirus infections on the care of febrile children. 1998.
    148. Romero J, Hinrichs S, Perry D, Et al. Impact of reverse transcription-polymerase chain reaction diagnosis of enterovirus infections on the care of febrile children. Pediatric Research. 1998.
    149. Romero J, Magelli M, Hinrichs S, Et al. Reverse transcription-polymerase chain reaction diagnosis of enterovirus infections in febrile children results in reduced health care expenditures. Infectious Diseases Society of America. 1998; 201.
    150. Rotbart HA, Brennan PJ, Fife KH, Romero J, Et al. Enterovirus meninigitis in adults. Clin Infect Dis. 1998; 27(4):896-898.
    151. Dunn JJ, Tracy SM, Romero J. The 5' untranslated region (5' UTR) of a wild-type coxsackievirus B3 (CBV3) strain attenuates the cardiovirulent phenotype of CBV3/20. 17th Annual American Society for Virology Scientific Program. 1998.
    152. Romero J, Hinrichs S, Perry D, Kruger R, Magelli M. Reverse transcription-polymerase chain reaction diagnosis of enterovirus infections in febrile children reduces duration of hospitalization, antibiotic administration and results in reduced health care costs. 15th Annual Meeting of the Minority Medical Faculty Development Program. 1998.
    153. Romero J, Bures E, Bradrick S, Price C. Molecular epidemiology of coxsackievirus B3 in the United States: 1949-1998. Pediatric Research. 1998.
    154. Romero J, Kirk C, Dunn J, Et al. Molecular and phenotypic characterization of a myocarditic coxsackievirus B3 (CVB3) isolate. Infectious Diseases Society of America. 1998; 134.
    155. Boken DJ, Romero J, Cavalieri SJ. Sphingomonas paucimobilis bacteremia: Four cases and review of the literature. Infect Dis Clin Prac. 1998; 7:286-291.
    156. Romero J. Complete capsid amino acid sequences of 14 wild-type coxsackievirus B3 (CBV3) isolates. 1997.
    157. Romero J. Echovirus-coxsackievirus chimeras for the evaluation of the role of the echovirus 5' nontranslated region (5' NTR) in pathogenesis. 1997.
    158. Romero J, Lieben E, Tracy SM, Et al. Echovirus-coxsackievirus chimeras for the evaluation of the role of the echovirus 5' nontranslated region (5' NTR) in pathogenesis. Pediatric Research. 1997.
    159. Romero J, Price C, Dunn JJ. Genetic divergence among the group B coxsackieviruses. Curr Top Microbiol Immunol. 1997; 223:81-96.
    160. Romero J, Dunn JJ, Leser JS, Et al. Complete capsid amino acid sequences of 14 wild-type coxsackievirus B3 (CBV3) isolates. 16th Annual American Society for Virology Scientific Program and Abstracts. 1997.
    161. Chapman NM, Romero J, Pallansch MA, Tracy S. Sites other than nucleotide 234 determin cardiovirulence in natural isolates of coxsackievirus B3. J Med Virol. 1997; 52:258-261.
    162. Romero J. Potential health care cost savings from PCR-based rapid diagnosis of enteroviral meningitis. 1996.
    163. Romero J. Genetic diversity and molecular epidemiology among coxsackievirus B2 (CVB2) during a community outbreak. 1996.
    164. Tracy S, Chapman NM, Romero J, Ramsingh AI. Genetics of coxsackievirus B cardiovirulence and inflammatory heart muscle disease. Trends Microbiol. 1996.
    165. Ehrhardt AF, Sanders CC, Romero J, Leser JS. Sequencing and analysis of four new Enterobacter ampD alleles. Antimicrob Agents Chemother. 1996; 40(8):1953-1956.
    166. Tracy S, Chapman N, Romero J, Currey K, Shapiro B. Mutations at position 234 in coxsackieviral 5' NTR. 15th Annual American Society for Virology Scientific Program and Abstracts. 1996.
    167. Romero J, Tracy SM, Pong AL, Hinrichs SH, Leser JS. Genetic diversity and molecular epidemiology among coxsackievirus B2 (CVB2) during a community outbreak. Pediatric Research. 1996.
    168. Rotbart HA, Brennan PJ, Fife KH, Romero J, Et al. Enterovirus (EV) meningitis (M) in adults. 36th Interscience Conference on Antimicrobials Agents and Chemotherapy Abstracts. 1996.
    169. Romero J, Tracy SM, Chapman NM, Leser JS. Chimeric coxsackievirus B3 as a vehicle to study the echovirus 5' nontranslated region (5'NTR). 15th Annual American Society for Virology Scientific Program and Abstracts. 1996.
    170. Romero J, Hinrichs SH, Cavalieri SJ, Perry D, Leser JS, Onyeuku J. Potential health care cost savings from PCR-based rapid diagnosis of enteroviral meningitis. Pediatric Research. 1996.
    171. Tracy S, Chapman N, Ramsingh A, Romero J, Curry K, Shapiro B, Barry W, Chin T, Hufnagel G. The Role of Immune Mechanisms in Disease. Coxsackievirus genetics and the cardiovirulent viral phenotype. 1996.
    172. Tu Z, Chapman NM, Hufnagel G, Tracy S, Romero J, Barry WH, Zhao L, Curry K, Shapiro B. The cardiovirulent phenotype of coxsackievirus B3 is determined at a single site in the genomic 5' nontranslated region. J Virol. 1995; 69(8):4607-4618.
    173. Ehrhardt A, Sanders C, Romero J, Leser J. Sequencing and analysis of four new Enterobacter ampD alleles. Interscience Conference on Antimicrobial Agents and Chemotherapy. 1995.
    174. Rotbart HA, Romero J. Human Enterovirus Infections. Laboratory diagnosis of enterovirus infections. 1995.
    175. Romero J, Rotbart HA. Sequence analysis of the downstream 5' nontranslated region of seven echoviruses with different neurovirulence phenotypes. J Virol. 1995; 69:1370-1375.
    176. Romero J, Leser JS, Tracy S, Chapman N, Winters D. Amino acid sequence variation in the major surface loop (VP2 E-F) of the cell receptor site from 8 clinical isolates of coxsackievirus B3. Pediatric Research. 1995.
    177. Chapman N, Tu Z, Hufnagel G, Tracy S, Romero J, Barry W, Zhao L, Currey K. Determination of genetics and mechanism of coxsackievirus B3 cardiovirulence. 95th General Meeting of American Society for Microbiology. 1995.
    178. Levin MJ, Romero J. Current Pediatric Diagnosis and Treatment. Infections: Viral and Rickettsial. 1994.
    179. Romero J, Ogle JW. Arboviral infections in the US: Encephalitis, Colorado tick fever and hantavirus. Seminars in Pediatric Infectious Diseases. 1994; 5:95-101.
    180. Romero J, Rotbart HA. PCR- Based Diagnostics of Infectious Organisms. Polymerase chain reaction strategies for the detection of the human enteroviruses. 1994.
    181. Romero J. Pediatric tuberculosis. Current Opinion in Infectious Diseases. 1994; 7:374-381.
    182. Romero J, Tracy S, Chapman N, Gauntt C. Genetic variation in coxsackievirus B3 genomes. 13th Annual American Society for Virology Scientific Program and Abstracts. 1994.
    183. Romero J. Genomic Variation of Coxsackievirus B3. 1994.
    184. Romero J, Rotbart HA. Sequence diversity among enteroviruses with different neurovirulence phenotypes. Pediatric Research. 1993.
    185. Romero J. Sequence diversity among enteroviruses with different neurovirulence phenotypes. 1993.
    186. Romero J, Rotbart HA. Selective amplification and partial sequence analysis of the 5'NTR of seven enteroviruses with different neurovirulence phenotypes. 12th Annual American Society for Virology Scientific Program and Abstracts. 1993.
    187. Romero J, Rotbart HA. Selective amplification and partial sequence analysis of the 5'NTR of seven enteroviruses with different neurovirulence phenotypes. 1993.
    188. Romero J. Tick-borne diseases of the United States. Contagious Comments. 1992; 12:1-5.
    189. Romero J. Tick-borne diseases of the United States- Update 1992. 1992.
    190. Doski JJ, Priebe CJ Jr., Driessnak-Hill M, Smith T, Kane P, Romero J. Corticosteroids in management of unresectable plasma cell granuloma (inflammatory psudeotumor) of the lung. J Pediatr Surg. 1991; 26:1064.
    191. Biancaniello TM, Romero J. Bacterial endocarditis after adjustment of orthodontic appliances. J Pediatr. 1991; 118:248.
    192. Romero J, Rotbart HA. Discriminant enteroviral replication in U937 cells: a candidate model for monocyte/enterovirus interactions. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy Program and Abstracts. 1990.
    193. Romero J, Rotbart HA. Discriminant enteroviral replication in U937 cells: a candidate model for monocyte/enterovirus interactions. 1990.
    194. Romero J, Putnak R, Wimmer E. Enteroviral capsid protein VP3 as a group antigen for the enteroviruses. 1988.
    195. Romero J, Putnak R, Wimmer E. Enteroviral capsid protein VP3 as a group antigen for the enteroviruses. Pediatric Research. 1988.
    196. Wimmer E, Kuhn RJ, Toyoda H, Nicklin MJH, Diamond DC, Murray MG, Romero J. Chemical and biologic properties of the poliovirion. Biologic Chem. 1986.
    197. Romero J, Putnak R, Wimmer E. The use of poliovirus proteins VP3 and 2C as group antigens for the detection of enteroviral infections by indirect immunofluorescence. Poster session presented. 1986.
    198. Romero J, Putnak R, Wimmer E. The use of poliovirus proteins VP3 and 2C as group antigens for the detection of enteroviral infections by indirect immunofluorescence. Pediatric Research. 1986.
    Romero's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _